简体中文

Surabhi Bajpai, MD

Associate Director, Scientific and Medical Services

Bio

Leveraging her training in medicine and radiology, Surabhi has led the imaging components of approximately 50 oncology trials – both solid tumors and hematology malignancies –  and provided consultation on complicated aspects of standardized response assessment criteria. Her expertise in Multiple Myeloma, Lymphoma, and CLL enables her to provide clear guidance to clinical trial sponsors and communicate complexities of criteria to independent reviewers to avoid heterogeneity.

Role at Calyx

- Provide medical interpretations to projects conducting complex clinical trials, both in solid tumor and hematology malignancies

- Contributes not only with imaging aspects but also with complex clinical data and protocol consultation in several CAR-T and other immune- oncology trials

Industry Experience

- Dr. Bajpai is a clinical radiologist board certified from India. She has extensive training in basic and advanced imaging modalities including CT and MRI.

- After her residency training, Dr. Bajpai has worked as a research fellow in radiology at Massachusetts General Hospital, Boston for three years focusing on several research projects related to applications of CT and MRI in the realm of Abdominal Imaging.

- During her research fellowship, she focused on studying the role of imaging as a biomarker in monitoring response to various systemic and loco-regional therapies. Dr. Bajpai has presented her several scientific abstracts and educational exhibits at prestigious international meetings such as Radiological Society of North America (RSNA) and American Roentgen Ray Society (ARRS). She has authored and co-authored several peer reviewed publications and text book chapters.

- Since the past four years at PAREXEL informatics, she has provided medical interpretations to projects conducting complex clinical trials, both in solid tumor and hematology malignancies

Academic Experience

- Dana Farber/Harvard Cancer Center, Boston, MA, USA, Tumor Imaging Metrics Core (TIMC) Imaging Reviewer Certification, 2016.

- Research Fellowship in Division of Abdominal Imaging and Intervention, Massachusetts General Hospital, Boston, MA, USA. 2012- 2015.

- DMRD (Diploma in Medical Radiodiagnosis) from Kasturba Medical College, Manipal, India. 2008.

- MBBS (Medical School) from Kasturba Medical College, Mangalore, India. 2005 and included one year of clinical rotating internship.

Therapeutic Experience

Strong experience in Oncology by medically and scientifically designing, leading and managing the imaging component of clinical trials, developing numerous protocols and imaging charters with various indications and various complexities, in phase I, II and III, with and without regulatory submission.

Experience in Oncology trials at PAREXEL Informatics as Scientific Consultant:
- Lymphoma (Non-Hodgkin's & Hodgkin’s Disease) (Phase II/III)
- Multiple Myeloma (Phase III)
- Urothelial cancer (Phase Ib)
- Endometrial cancer (Phase IIb)
- Renal cancer (Phase IIb/III)
- Cholagiocarcinoma and Gall Bladder cancer (Phase Ib)
- Breast Cancer (Phase IIb)
- Smoldering Myeloma (Smoldering Myeloma) (Phase III)
- Pediatric Lymphoma (Phase II/III)
- Gastric cancer/ Gastroesophageal cancer (Phase II/III)
- Waldenstrom Macroglobulinemia (Phase I/III)
- Chronic Lymphocytic Leukemia (Phase III)

Scientific Exhibitions

- Bajpai S, Sripathi S, Rajagopal KV, VRK Rao. CT features of GIST. Indian Radiological & Imaging Association Annual meeting 2008.

- Bajpai S, Singh AH, Kambadakone A, Catalano OA, Blake MA, Sahani DV. Quantitative hepatic Imaging: Current and Emerging Trends. American Roentgen Ray Society Annual meeting 2009.

- Kakkar C, Polnaya A, Koteshwar P, Bajpai S. Right Lower quadrant: Too similar but actually too different. Radiological Society of North America Annual meeting 2011.

- Kulkarni N, Bajpai S, Fuentes J M, Kambadakone A, Sahani DV. Strategies in Reducing Patients' Radiation Exposure with MDCT for Gentiourinary Applications. Radiological Society of North America Annual meeting 2012.

- Kulkarni N, Bajpai S, Shepard JO, Digumarthy SR, Heist RS, Sahani DV. Morphologic and Functional Image Biomarkers of Treatment Response in Advanced Non-Small Cell Lung Cancer. Radiological Society of North America Annual meeting 2012.

- Kakkar C, Shetty CM, Bajpai S, Rajagopal KV, Sambhaji CJ, Prakashini K. Lumpy Bumpy Liver: An Imaging Review of Hepatic Contour Abnormalities. Radiological Society of North America Annual meeting 2012.

- Kakkar C, Bajpai S, Prakashini K, Sambhaji CJ, Rajagopal KV, Rao VRK. Hepatic Tuberculosis: A Review of Sonographic and CT Imaging Features. Radiological Society of North America Annual meeting 2012.

- Kakkar C, Shetty CM, Bajpai S, Prakashini K, Sambhaji CJ, Rajagopal KV. Telltale Signs of Peripheral Neurogenic Tumors on Magnetic Resonance Imaging. Radiological Society of North America Annual meeting 2012.

- Bajpai S, Guimaraes AR, Kambadakone AR, Arellano RS, Sahani DV. Image guided treatment in hepatobiliary system: Role of imaging in treatment planning and post treatment evaluation. Radiological Society of North America Annual meeting 2013.

- Narang J, Bajpai S, Jarecha R, Ludajic K, Karve S, Kheterpal A, Mikhael J. Imaging in Multiple Myeloma: Independent review perspective for IMWG 2016 response assessment. XVIIth International Myeloma Symposium, Boston, September 2019.

- Jayant Narang, Surabhi Bajpai, Rudresh Jarecha, Sayali Karve, Katarina Ludajic, Manish Sharma, Oliver Bohnsack. Retrospective comparison of Cheson 2007 and Lugano classification criteria in independent review assessment of FDG-avid lymphomas. ASCO 2019.

- Jayant Narang, Surabhi Bajpai, Rudresh Jarecha, Sayali Karve, Katarina Ludajic, Manish Sharma, Shweta Narang, Michael O'Connor. Comparison of CT and PET-Based Assessments per Lugano Criteria in FDG-Avid Lymphoma- a Retrospective Analysis of Independent Review Assessments. ASH 2019, published in Blood (2019) 134 (Supplement_1): 5277

- Bohnsack O, Narang J, Bajpai S, Lesch M, Jarecha R, Sharma M, Lencioni R, Response assessments in hepatocellular carcinoma - What is the best criteria to utilize? mRECIST or RECIST 1.1? - A retrospective meta-analysis of multiple phase III trials; ePoster #168 at ESMO Asia 2020.

- Narang J, Bajpai S, Jarecha R, Sharma M, Bohnsack O, Comparison of response using mRECIST versus RECIST 1.1 Criteria in advanced hepatocellular carcinoma – A retrospective analysis of multi-center clinical trials; ePoster at ASCO 2020.

- Manish Sharma. Oliver Bohnsack. Rudresh Jarecha, Jayant Narang, Anitha Singhareddy, Surabhi Bajpai. Identification of new lesions with disease progression in Ovarian cancer per RECIST 1.1; ePoster at ASCO 2020

- Jayant Narang, Surabhi Bajpai, Rudresh Jarecha, Christiana Caplan Dana Macdonald, Gabriele Pradella, Manish Sharma, Bruce Cheson ``The Clinical Relevance of Residual, Persistent and Elongated Abnormal Sized Nodes by LDi+ in Patients with CLL, otherwise in CR. Blood (2020) 136 (Supplement 1): 34–35.

- Surabhi Bajpai, Jayant Narang, Shweta Narang ,Ravikanth Mankala, Rudresh Jarecha, Manish Sharma Mantle Cell Lymphoma: Incidence of Gastrointestinal Involvement and Correlation with Overall Response- Retrospective Review of Multiple Multicenter Trials Blood (2020) 136 (Supplement 1): 33–34.

- Bajpai S, Narang J, Narang S, Mankala R, Jarecha R, Sharma M. Mantle Cell Lymphoma : Incidence of Gastrointestinal Involvement and Correlation with Overall Response- Retrospective review of Multiple Multicenter Trials.

Publications

- Bajpai S, Sahani DV. Recent progress in imaging of colorectal liver metastases. Current Colorectal Cancer reports 2009; 5: 99-107.

- Konstantinidis IT, Bajpai S, Kambadakone AR, Tanabe KK, Berger DL, Zheng H, Sahani DV, Lauwers GY, Fernandez-del Castillo C, Warshaw AL, Ferrone CR. Gallbladder lesions identified on ultrasound - lessons from the last 10 years. J Gastrointest Surg. 2012 Mar; 16(3): 549-53. PMID:22108768

- Wright AP, Desai AP, Bajpai S, King LY, Sahani DV, Corey KE. Gaps in
Recognition and Evaluation of Incidentally Identified Hepatic Steatosis. Dig Dis Sci.
2014 Sep 5. PMID:25190263

- Sahani DV, Bajwa MA, Andrabi Y, Bajpai S, Cusack JC. Current status of imaging
and emerging techniques to evaluate liver metastases from colorectal carcinoma. Ann
Surg. 2014 May;259(5):861-72. PMID:24509207

- Bajpai S, Kambadakone A, Guimaraes A, Arellano RA, Gervais DA, Sahani DV.
Image guided treatment in the Hepatobiliary System: Role of Imaging in Pretreatment
Planning and Posttreatment evaluation. Radiographics. 2015 Sep-Oct;35(5):1393-418.PMID:26252365.

- Kakkar C, Shetty CM, Koteshwara P, Bajpai S. Telltale sign of Peripheral Neurogenic Tumors on Magnetic Resonance Imaging. Indian Journal of Radiology and Imaging. 2015 Nov;25(5):455-458.

- Jayant Narang, Surabhi Bajpai, Rudresh Jarecha, Sayali Karve, Katarina Ludajic, Manish Sharma, Shweta Narang, Michael O'Connor. Comparison of CT and PET-Based Assessments per Lugano Criteria in FDG-Avid Lymphoma- a Retrospective Analysis of Independent Review Assessments. ASH 2019, published in Blood (2019) 134 (Supplement_1): 5277.

Presentations

- Bajpai S, Konstantinidis I, Kambadakone A, Ferrone CR, Sahani DV. Sonographic and Histopathological Correlation of Gallbladder Polyps Detected on Ultrasound: A Retrospective Review in 184 Patients. Radiological Society of North America Annual meeting 2009.

- Agrawal MD, Bajpai S, Oliveira GR, Kalva SP, Fuentes JM, Hayano K, Sahani DV. Dual energy CT for reducing iodine dose in Aorto-iliac Imaging. American Roentgen Ray Society Annual meeting 2013.

- Wright A, Bajpai S, Sahani DV, Corey K. Gaps in primary care physician evaluation of incidentally identified hepatic steatosis. Digestive Disease week 2013.

- Bajpai S, Eisner BH, Choy G, Sahani DV. Trends in MDCT utilization and its impact on radiation dose for diagnosis of urolithiasis in an emergency setting. Radiological Society of North America Annual meeting 2013.

- Bajpai S, Agarwal S, Hong TS, Zhu AX, Sahani DV. Assessing effectiveness of proton stereotactic radiotherapy (PSRT) for liver metastases with MRI. Radiological Society of North America Annual meeting 2013.

- Agrawal MD, Bajpai S, Oliveira GR, Kalva SP, Fuentes JM, Hayano K, Sahani DV. Reduced iodine dose single source dual-energy CT angiography of abdomen for assessment of aorto-iliac disease: Is this Killer application for Dual-energy CT? Radiological Society of North America Annual meeting 2013.

- Bajpai S, Andrabi Y, Wright R, Gervais DA, Sahani DV. CT depicted pancreatic parenchymal attenuation as a potential screening biomarker for predicting glucose intolerance and patient body habitus. Radiological Society of North America Annual meeting 2013.

- Bajpai S, Wright AP, Corey K, Gervais DA, Sahani DV. Structured reporting of incidentally detected hepatic steatosis in abdominal CTs: Impact on physician practices and patient management. Radiological Society of North America Annual meeting 2013.

Abstracts

- Sectional editor. In Sahani and Samir. Textbook of Abdominal Imaging.2nd Edition

- Bajpai S, Sahani DV. Abdominal Visceral Imaging. In William RR Eds. Clinicians' Guide to Imaging.

- Bajpai S, Sahani DV. Perfusion Imaging CT and MR. In Gore RM and Levine MS. Textbook of Gastrointestinal Radiology.

- Chew M, Bajpai S, Hahn P. Dilated Bile Ducts. In Sahani and Samir. Textbook of Abdominal Imaging.2nd Edition.

- Petralia G, Bajpai S, Morana G. Gall Bladder and Bile Duct Functional Imaging. In Sahani and Samir. Textbook of Abdominal Imaging. 2nd Edition

- Bajpai S, Uppot RN. Image guided Therapy. In Sahani and Samir. Textbook of Abdominal Imaging.2nd Edition.

- Sharma M, Jarecha R, Ludajic K, Narang J, Karve S, Bajpai S, O’Connor M, Singareddy A. Impact of PET on imaging related endpoints in lymphoma trials. - White Paper.

Associations and Affiliations

Radiological Society of North America (2008 – Present)
American Roentgen Ray Society (2008 – Present)

Library

Utilizing Medical Imaging to Support Accelerated Approval

Earning the FDA’s prized Breakthrough Therapy designation is just the beginning of the race, one that likely requires the use of an imaging surrogate for preclinical evidence and accelerated approval.
Read more

Impact of PET on imaging related endpoints in lymphoma trials

We know that PET imaging is critical in determining response assessments in hematology trials but what do you do when PET scans are not always available? See what our experts have to say.
Read more

Behind the Breakthrough

Earning the FDA’s prized Breakthrough Therapy designation is just the beginning of the race, one that likely requires the use of an imaging surrogate for preclinical evidence and accelerated approval.
Read more

Reviewer Performance Monitoring in Blinded Independent Central Review Setting

This white paper reviews how the assessment of imaging data in support of surrogate endpoints by an independent entity reduces evaluation bias and improves assessment consistency in clinical trials.
Read more

Stay Updated

Never miss a beat. Sign up to receive emails covering industry news and useful content to help you advance clinical development.

  • This field is for validation purposes and should be left unchanged.